This collection of health news showcases a range of significant developments: measles cases are surging in Texas and New ...

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) gapped up prior to trading on Friday after Citigroup raised their price target on the stock from $338.00 to $351.00. The stock ...

The document outlines various health-related news, including a measles outbreak in Texas and New Mexico, UNICEF's aid crisis ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alnylam Pharmaceuticals's whale activity within a strike price range from $210.0 to $340 ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Alnylam Pharma (ALNY) stock rocketed higher on Friday after the pharmaceutical company received approval from the U.S. Food and Drug ...

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...

Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...